Showing results (1-10 of 16) with videos related to
Sort By:
Pageof 2
Der Internist|March 3, 2018
[Current drug treatment of hepatitis C : Useful therapy algorithms taking into consideration economical aspects]K Deterding, M P Manns, H WedemeyerZeitschrift Fur Gastroenterologie|July 17, 2009
Successful treatment of fulminant hepatitis B during pregnancyA Potthoff, K Rifai, H Wedemeyer, et al.Journal of Viral Hepatitis|July 2, 2009
Virological and clinical characteristics of delta hepatitis in Central EuropeB Heidrich, K Deterding, H L Tillmann, et al.Deutsche Medizinische Wochenschrift (1946)|April 12, 2012
[Knowledge and management of hepatitis B virus infected patients in Germany]K Deterding, S Heidelberger, B Wiebner, et al.Zeitschrift Fur Gastroenterologie|January 20, 2007
Steroid treatment for severe acute cryptogenic hepatitisA Potthoff, K Deterding, C Trautwein, et al.Journal of Viral Hepatitis|June 23, 2011
Adefovir serum levels do not differ between responders and nonrespondersK Deterding, L Naesens, M Buti, et al.Zeitschrift Fur Gastroenterologie|August 17, 2012
[Costs of guideline-based treatment of hepatitis B patients in Germany]J T Stahmeyer, H Becker, S Heidelberger, et al.Alimentary Pharmacology & Therapeutics|December 6, 2017
Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosisF Mettke, B Schlevogt, K Deterding, et al.Infection|December 18, 2007
Clearance of chronic HCV infection during acute delta hepatitisK Deterding, S V Pothakamuri, V Schlaphoff, et al.Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|April 18, 2015
Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-γ-induced protein 10 levels in HBV/HCV-coinfected patientsS B Wiegand, J Jaroszewicz, A Potthoff, et al.Pageof 2